News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Lab-developed intestinal organoids form mature human tissue in mice

Lab-developed intestinal organoids form mature human tissue in mice Date: Researchers have successfully transplanted “organoids” of functioning human intestinal tissue grown from pluripotent stem cells in a lab dish into mice – creating an unprecedented model for studying diseases of the intestine.Reporting their results Oct. 19 online in Nature Medicine, scientists from Cincinnati Children’s Hospital Medical Center said that, through additional translation


2. Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in

Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014 Date:10/11/2014Detailed results of four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014Secukinumab is the first selective interleukin-17A (IL-17A) inhibitor with Phase III data to demonstrate efficacy and improve symptoms in patients with PsA and ASData will inclu


3. Boost for liver disease trial

Boost for liver disease trial Date: 24/11/2014Researchers from the University of Edinburgh have received funding to start testing the therapy in patients within the next year.It will be the world’s first clinical trial of a new type of cell therapy to treat liver cirrhosis, a common disease where scar tissue forms in the organ as a result of long-term damage.The Edinburgh team has received funding from the Medical Research Council and Innovate UK to investigate the disease, which clai


4. Publication of Circular and Notice of General Meeting relating to the

Publication of Circular and Notice of General Meeting relating to the proposed major transaction with Novartis Date: 25/11/2014GlaxoSmithKline plc (the “Company”, “GSK”) announced a major three-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses (the “Transaction”).The proposed Transaction would substantially strengthen two of our core businesses in vaccines and consumer healthcare and cr


5. Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease

 Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease Date:01/12/2014 Reimbursed via the Pharmaceutical Benefits Scheme from 1st December 2014 - Administered using a new dry powder inhaler called Ellipta1GlaxoSmithKline (GSK) has welcomed the listing of Incruse Ellipta (umeclidinium) on the Australian Pharmaceutical Benefits Scheme (PBS) from December 1st 2014 as a long term once-daily, maintenance bronchodilator t



Page 2 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2018